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Abstract: Brain metastases (BM) develop in about 30% of all cancer patients. Surgery 
plays an important role in confirming neuropathological diagnosis, relieving mass effects 
and improving the neurological status. To select patients with the highest benefit from 
surgical resection, prognostic indices (RPA, GPA) have been formulated which are solely 
focused on survival without considering neurological improvement. In this study we 
analyzed the impact of surgical resection on the neurological status in addition to overall 
survival in 206 BM patients. Surgical mortality and morbidity was 0.0% and 10.3% 
respectively. New neurologic deficits occurred in 6.3% of all patients. The median overall 
survival was 6.3 months. Poor RPA class and short time interval between diagnosis of 
cancer and the occurrence of BM were independent factors predictive for poor survival. 
Improvement of neurological performance was achieved in 56.8% of all patients, with the 
highest improvement rate seen in patients presenting with increased intracranial pressure 
and hemiparesis. Notably, the neurological benefits were independent from RPA class. In 
conclusion, surgical resection leads to significant neurological improvement despite poor 
RPA class and short overall survival. Considering the low mortality and morbidity rates, 
resection should be considered as a valid option to increase neurological function and 
quality of life for patients with BM. 
OPEN ACCESS
Int. J. Mol. Sci. 2013, 14 8709 
 
Keywords: resection; recurrence; survival; neurological status; prognosis; brain metastases 
 
1. Introduction 
Brain metastases (BM) are by far the most frequent intracranial tumor in adults, outnumbering 
primary brain tumors by about four times [1]. Recently, an apparent increase in the incidence of brain 
metastases has been observed [2], which may be related to the higher sensitivity of modern 
neuroradiological imaging technology [3]. In specific cancer types, for which molecular treatment 
strategies are now available, a significantly higher percentage of BM have been detected [4]. Since 
BM generally occur late in the course of the disease, the prolonged overall survival induced by 
advanced treatment options allows for BM [5]. Alternatively, certain large-molecule biological agents 
such as trastuzumab do not properly penetrate the blood-brain barrier [6]. This leads to an organ 
specific failure of these molecular strategies due to micrometastases in the brain, which are 
sequestered behind the vascular barrier. In addition to poor overall survival, with a median survival 
time between 5 to 12 months [7], about 90% of all BM patients show neurological impairment which 
negatively impacts quality of life [8]. Surgical resection plays an important role in relieving mass 
effects and decompressing eloquent areas of the brain causing improvement of neurological  
status [9]. Recently, two randomized clinical trials demonstrated that surgical resection prolongs 
overall survival compared to whole brain radiation treatment (WBRT) alone [10,11]. To benefit from 
surgical resection, a patient must be medically suitable, with a disease prognosis amenable to benefit 
from local central nervous system tumor control [12]. This has led to the formulation of prognostic 
indices such as the RPA classification, categorizing patients with a Karnofsky performance score 
(KPS) of more than 70, age under 65 years, with controlled primary tumor and no extracranial 
metastases as most suitable for surgical resection [13,14]. However, these algorithms to select suitable 
patients for resection were solely focused on overall survival, without considering neurological 
improvement symptom relief and personal independence as an important endpoint for QOL, especially 
in a palliative setting [15]. Data regarding detailed evaluations of specific neurological impairment 
patterns and their response to surgical treatment were lacking. We therefore investigated the impact of 
surgical resection in a cohort of 206 BM patients on neurological status in addition to overall survival. 
We have also identified independent factors predictive for poor outcome in this patient population.  
2. Materials and Methods 
The study was approved by the University Regensburg Ethics Committee and conducted in 
accordance to the ethical standards of the Helsinki Declaration. Patient´s written consent was obtained 
whenever possible, and all study results were stored and analyzed anonymously. We analyzed a cohort 
of 206 patients (female/male: 84/122) who were initially diagnosed with metastatic brain disease at a 
mean age of 61.1 years (range: 23.4–83.9) and consecutively treated with microsurgical resection for 
BM. A detailed description of patient characteristics is provided in Table 1. Exclusion criteria were 
biopsy only, histology other than metastatic tumor and age younger than 18 years. Indication for 
surgical resection was based on either decompressing a mass lesion or establishing a histological 
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diagnosis. Intraoperative ultrasound was used in 96.1% of all cases; neuronavigation and awake 
craniotomy with direct cortical and subcortical stimulation were used in 63.6% and 5.3%, respectively. 
Preoperative steroid medication was given in 95.6% of all cases, which was tapered postsurgically in 
75.6% of all patients on steroid medication. All patients received MRI scanning prior to surgery and 
within 72 hours after surgery to evaluate the extent of resection (EOR), categorized as gross total 
resection (GTR, 92.2%) or subtotal resection (STR, 7.8%). In case of multiple metastases, the lesion 
with the largest mass effect leading to clinical impairment was resected. No more than 3 tumors were 
removed in one session. Intratumoral hemorrhage was detected in 16.5% on the preoperative MRI, 
leading to emergency evacuation of the tumor in 4.4% of all patients. Radiotherapy was administered 
as WBRT with 30–35 Gy to 64.6% of all patients, from which 18 patients (13.5%) received additional 
stereotactic boost radiation of the tumor bed. Adjuvant chemotherapy was administered postsurgically 
in 35.4% of all patients. From all patients, 9.7% corresponded to RPA class I, 77.7% and 12.6% to 
class II and III respectively. Follow up was completed up to March 2012 by reviewing outpatient 
records and contacting the patient, a family member or the patient´s primary physician. No patient was 
lost for follow up. The median follow up time was 6.1 months. Overall survival was analyzed using the 
Kaplan-Meier procedure, with Log-rank analysis utilized to calculate differences in overall survival. 
To isolate independent predictive factors for survival, multivariate analysis was performed using the 
Cox hazard regression model [16]. Quality of life and neurological deficits were quantified with the 
Medical Research Council Neurological Performance Score [17] (MRC-NPS; Table 2) and the 
Karnofsky Performance Score (KPS) respectively. Differences in improvement rates were analyzed by 
performing rates and proportions testing (chi square analyses). Additionally, signs of increased 
intracranial pressure (ICP), hemiparesis, visual deficits and aphasia were recorded preoperatively, at 
discharge and at the last follow up exam.  
Table 1. Characteristics of patients with brain metastases receiving surgical resection  
(n = 206). 
Variable Number  %  
Age (years)   
Mean  61.6  
Range 23.4–83.9  
Gender    
Male 122 59.2 
Female  84 40.8 
Primary tumor    
Lung cancer 70 34.0 
Melanoma 30 14.5 
Breast cancer 28 13.6 
Colon cancer 20 9.7 
Renal cancer  16 7.8 
CUP 9 4.4 
Urothel cancer 7 3.4 
Prostate 4 1.9 
Other 22 10.7 
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Table 1. Cont. 
Variable Number  %  
Systemic disease    
Controlled 99 48.1 
Active 107 51.9 
Time of brain metastases    
Synchronous 64 31.1 
Metachronous 142 68.9 
Status of metastasis    
Solitary 61 29.7 
Singular 60 29.1 
Multiple 85 41.2 
Table 2. Medical Research Council-Neurological Performance Status Scale (MRC-NPS). 
Grade Performance 
1 No neurological deficit 
2 Some neurological deficit but function adequate for useful work 
3 
Neurological deficit causing moderate functional impairment e.g., ability to move limbs 
only with difficulty, moderate dysphasia, moderate paresis, some visual disturbance 
4 
Neurological deficit causing major functional impairment e.g., inability to use limbs,  
gross speech or visual disturbances 
5 No useful function-inability to make conscious responses 
3. Results 
The most frequent primary cancer types encountered were lung cancer (34%), malignant melanoma 
(14.5%), breast (13.6%) and colon cancer (9.7%) (Table 1). The most frequent location was the 
infratentorial compartment (Figure 1), followed by the frontal and parietal lobes. The median diameter 
of the tumors was 3.2 cm (range: 7.0–2.2 cm). Solitary metastases, defined as a single metastatic lesion 
in the brain without evidence for extracerebral metastases, occurred in 29.7% of all cases, 29.1% of all 
patients presented with a single metastatic lesion (i.e., one brain metastasis with additional extracerebral 
metastases), while 41.2% of all patients had multiple brain metastases. Surgical mortality and 
morbidity was 0.0% and 10.3% respectively. New neurologic impairment or worsening of pre-existing 
deficits occurred in 6.3% of all patients resulting in an overall morbidity rate of 16.6% (Table 3). The 
local recurrence rate was 22.1% with a one-year recurrence rate of 18.5%. Post-surgical radiation 
therapy significantly reduced the recurrence rate (HR 2.2; 95% CI 1.2–4.3; p = 0.025), whereas the 
extent of resection had no influence on the risk of recurrence (HR 0.75; 95% CI 0.3–1.8; p = 0.114). 
The median overall survival was 6.3 months. Patients corresponding to RPA class I showed a 
significantly better median overall survival (25.2 months) compared to patients in class II (6.7 months) 
and III (3.2 months) (0 < 0.001, Table 4, Figure 2A). In contrast, no significant difference in overall 
survival was detected between metachronous vs. synchronous occurrence of BM, EOR, or solitary, 
single or multiple metastases (Figure 2B–D). Multivariate analysis revealed poor RPA class and a 
short time interval between initial diagnosis of cancer and the first occurrence of BM as independent 
factors predicting short survival (Table 5). The majority of all patients presented with an impaired KPS 
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score (92.7%) which improved in 54.9% of all affected patients after surgery and at last follow up  
(p < 0.001; Figure 3). Similarly, the MCR-NPS rating was reduced indicating moderate to severe 
neurological deficits in 70.9% of the patients, which was again significantly improved in 56.8%  
(p < 0.001; Figure 3). The most frequent clinical symptoms in the study population were signs of 
increased ICP in 40.8% of all patients, which was completely resolved in 97.6% of all affected 
patients. Interestingly, hemiparesis, which occurred in 10.2% of the patients, was significantly 
improved postoperatively (p < 0.014); however visual field deficits and signs of aphasia were not 
improved by surgical resection (Table 6). The distribution of neurological impairment was 
significantly different within the RPA classes, with patients in class III presenting significantly more 
frequently with impaired MRC-NPS rating, hemiparesis and raised ICP. In contrast, the functional 
improvement rate was equally distributed throughout the RPA classes, indicating a significant benefit 
of neurological function and quality of life even in patients belonging to the worst prognostic group.  
Table 3. Surgical and neurological morbidity after surgical resection of brain metastases. 
Surgical morbidity  Patients  %  
CSF leakage  9  4.4  
Hemorrhage  6  2.9  
Wound infection  3  1.5  
Stroke  2  1.0  
New seizure  1  0.5  
n  21  10.3  
Neurological morbidity   
New neurological deficit  4  1.9  
Worsening of existing deficit  9  4.4  
n 13  6.3  
Total morbidity  34  16.6  
Table 4. Survival rates stratified by recursive partitioning analysis (RPA) classification. 
 Median survival (months)  1-year survival rate (%)  2-year survival rate (%)  
all 6.3  24.6  8.2  
RPA 1  25.2 43.5  39.1  
RPA 2 6.7  22.4  3.7  
RPA 3 3.2  21.7  4.3  
Table 5. Cox regression analysis of prognostic factors for survival. 
Parameter Hazard ratio 95% CI Low High p 
Age 0.02 0.993 1.021 0.882 
Tumor size 2.26 0.958 1.282 0.132 
Primary tumor 0.06 0.926 1.118 0.801 
Metachronous/synchronous 0.56 0.856 1.987 0.454 
RPA class 13.70 1.262 2.617 0.001 
Solitary/singular/multiple 1.53 0.862 1.308 0.215 
Time interval to metastasis 15.50 0.982 1.001 0.001 
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n (% affected) 
Resolved  
n (% affected) 
Improved  
n (% affected) 
Worsened  
n (% affected) 
p 
Increased ICP 84 (40.8%)  1 (1.2%)  82 (97.6%)  1 (1.2%)  0  0.001  
Hemiparesis  21 (10.2%)  12 (57.1%)  3 (14.3%)  6 (28.6%)  0  0.014  
Aphasia  25 (12.1%)  11 (44.0%)  4 (16.0%)  3 (12.0%)  7 (28.0%)  0.334  
Visual field defect  21 (10.2%)  18 (85.7%)  1 (4.8%)  0  2 (9.5%)  0.894  
Figure 1. Preoperative MRI of a patient with a cerebellar metastasis from lung cancer 
utilizing (A) T1 weighted, contrast enhanced and; (B) fluid attenuated inversion recovery 
sequences (FLAIR). Note the mass effect on the fourth ventricle and the significant 
perifocal edema. Panel C & D displays the postoperative scan demonstrating the 
decompression of the CSF pathways and the reduced edema immediately after resection.  
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Figure 2. Kaplan–Meier curves of the overall survival in patients with brain metastases 
receiving surgical resection. (A) RPA classification is significantly related to survival  
(p < 0.001), whereas (B) synchronous or metachronous occurrence of metastases,  
(C) extent of resection (GTR = gross total resection, STR = subtotal resection), as well (D) 
the metastatic status (solitary, singular or multiple) is not (p > 0.05). 
 
Figure 3. The bar graphs illustrate significant improvement of neurological status 
measured by the MRC-NPS system (black) and Karnofsky Performance Score (KPS) 
(white) after microsurgical resection of brain metastases (* p < 0.001).  
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4. Discussion 
Our study demonstrates that BM patients with a poor RPA rating resulting in a shorter overall 
survival time still show significant neuro-functional benefit from surgical resection. However, this 
analysis has several limitations: First, this is a retrospective design lacking the proper non - surgical 
control group. Second, both KPS and the MRC-NPS may not adequately reflect the exact 
neurocognitive status in this patient population. Third, volumetric data of tumor size is lacking which 
is important if comparing our surgical results against a radiosurgical series. These aspects need to be 
addressed in a future investigation using a prospective study design. According to the American 
Cancer Society, the 5-year survival rate for all cancers increased from 50% in 1974–1976 to 70% 
between 2000 and 2008 [18]. Advances in longer-term survival have even been greater for specific 
histologies such as breast cancer. However, the occurrence of brain metastases still marks the final 
stage of the disease accompanied with an exceptionally poor prognosis [7]. Two randomized clinical 
trials have demonstrated that surgical resection is superior to WBRT only [10,11], and that WBRT 
after resection significantly reduces the brain specific recurrence rate. [19]. This is in contrast to a 
report by Mintz et al., which failed to detect a significant beneficial effect of surgical resection [20]. 
However, the results of this study are controversial, since more than 45% of the patients followed in 
this trial had uncontrolled systemic disease and 40% presented with a Karnofsky score of 50 or  
less [9]. In the formerly mentioned trial by Patchell et al., 11% of all patents were found to have  
non-metastatic lesions, which highlights the importance of surgical resection to confirm the 
neuropathological diagnosis [10]. In addition to improved survival, surgical resection leads to 
reduction of mass effects with symptom relief, and decompression of the CSF pathways, especially in 
the posterior fossa, preventing occlusive hydrocephalus with life threatening complications [21–23]. 
According to our results, increased ICP and motor impairment such as hemiparesis are specifically 
amendable to surgical treatment, whereas aphasia and visual deficits are less beneficially influenced. 
However, since the majority of patients succumb to the exacerbation of their systemic disease, benefit 
from surgical resection of BM as an invasive strategy associated with significant morbidity, mortality 
and longer hospital stay was thought to be achieved only if patients have a prognosed life span of more 
than 6 months [24]. Recent developments such as functional MRI [25], neuro-navigation [26,27] and 
awake craniotomy [28] have caused a shift of paradigm in clinical neurosciences, including the 
surgical treatment of BM. The advent of modern technology has revolutionized the pre-operative 
workup, surgical trajectory planning and intra-operative monitoring with significant benefit to the 
patients regarding neurofunctional improvement and overall survival. This is reflected by the low 
morbidity and mortality rates in our study population, which is in accordance to other surgical  
series [9,29–31]. In addition, we observed significant improvement of the neurological status 
throughout the entire population independent from RPA classification. This indicates that tailoring the 
therapeutic decision process solely according to survival–based rating algorithms may not be an 
adequate strategy [32]. Recent studies have demonstrated that stereotactic radiosurgery (SRS) can lead to 
excellent tumor control and survival rates comparable to surgical evacuation [29,33,34]. However, since 
SRS does not primarily reduce mass effects and can induce regressive changes such as intratumoral 
hemorrhages [35], perifocal edema and radionecrosis [36], this treatment bears specific limitations 
especially in tumors larger than 3 cm in diameter. Accordingly, a recent study has detected significant 
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treatment–related neurological and non-neurological complications in 40% of 313 patients treated with 
SRS for BMs [37]. Evidently, SRS is a valid treatment option for patients with small, deep seated or 
multiple tumors located in surgically inaccessible areas [38]. However, in patients medically suited for 
surgical intervention, with tumors larger than 2 cm in diameter causing significant mass effects and 
neurological deficits, surgical evacuation should be considered as a beneficial treatment strategy for 
each individual patient independent of rigid prognostic indices.  
5. Conclusions 
In addition to short overall survival, BM patients frequently suffer from neurological impairment 
leading to poor quality of life. Surgical resection causes significant neuro-functional improvement in 
the majority of BM patients independent from RPA classification. Signs of increased intracranial 
pressure and motoric impairments are particularly susceptible to microsurgical decompression. 
Considering the low mortality and morbidity rates, resection should be considered as a valid option to 
increase neurological function and quality of life for patients with BM. 
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